newsfilter
← Latest News
Earnings Call Transcripts·

Septerna - 1781718 - SEPTERNA INC

  • Explicit Guidance:

    • SCP-479 (Hyperparathyroidism): Phase 1 trial readout expected in Q1 2027; Phase 2 trials targeted for second half of 2026; chronic toxicology studies to precede Phase 2 initiation to enable open-label extensions for Phase 3 patients.
    • SCP-204 (Graves' Disease/Thyroid Eye Disease): Phase 1 clinical initiation scheduled for Q1 2027; healthy volunteer data anticipated prior to end of 2027.
    • Novo Collaboration: First development candidate selected for advancement from the 5-target, 4-program portfolio established in mid-2025.
    • Clinical Endpoints (Phase 1 Targets):
      • SCP-479: Target endogenous PTH reduction of ~50% and serum calcium increase of ~0.5 mg/dL (starting dose) up to ~1.0 mg/dL (high dose).
      • SCP-204: Target endogenous TSH increase and suppression of thyroid hormones at high doses.
    • Project Half-Life Projections:
      • SCP-479: Actual human half-life observed at 3–4 days (vs. projected 40–80 hours); Urovipath (competitor) simulated half-life ~2.5 days.
      • SCP-204: Projected human half-life of 20–40 hours to support once-daily dosing.
  • Business-Segment Outlook:

    • SCP-479 (PTH1R Agonist): Positioning as an oral alternative to daily injectable peptides (e.g., Urovipath) to expand treatable population beyond severe patients to include moderate cases; potential for broader patient access due to lack of need for intact parathyroid tissue (unlike Encalerate).
    • SCP-204 (TSHR Antagonist): Dual target for Graves' disease and Thyroid Eye Disease (TED); potential for dose optionality to either normalize thyroid function or fully suppress it.
    • SCP-631 (MRG-Perox-2): Strategy shifting from large Phase 2 in Chronic Spontaneous Urticaria (CSU) to smaller, signal-finding studies to identify high-probability indications including migraine, interstitial cystitis, and asthma.
    • OSTEOPOROSIS PROGRAM: Developing a second PTH agonist distinct from SCP-479; requires a short-acting compound (anabolic effect) vs. the long-acting nature of the hyperparathyroidism drug.
    • NOVO PARTNERSHIP: Collaboration on 5 targets is advancing; Novo selected the first development candidate and plans to move it forward.
  • Market and Competitive Outlook:

    • Hyperparathyroidism Landscape: Addressing 70,000–80,000 U.S. patients; current standard of care (calcium/Vitamin D) considered suboptimal; Urovipath (injectable) is the current benchmark for peptide replacement.
    • Competitive Differentiation: Differentiation from Encalerate (calcium-sensing receptor agonist) based on mechanism; Encalerate requires intact parathyroid tissue (unavailable in post-surgical patients), whereas SCP-479 provides direct PTH replacement.
    • Mast Cell Program (X2/SCP-631): Exploring migraine as a key indication due to emerging data on mast cell activation and neuropeptide (PACAP) involvement; aiming for "best-in-class" profile via negative allosteric modulation.
  • Macro / Industry Outlook:

    • Regulatory/Development Strategy: Leveraging healthy volunteer data for proof-of-concept in rare diseases (hyperparathyroidism, Graves') based on the premise that receptor biology is consistent between healthy volunteers and patients.
    • Pricing Strategy: No explicit pricing guidance provided; focus remains on demonstrating patient benefit over existing therapies before pricing discussions.
  • Strategic Initiatives:

    • Oral Small Molecule Platform: Continued refinement of the "Native Complex Platform" to enable oral small molecules that mimic peptide functionality for difficult GPCR targets.
    • Clinical Trial Design: Implementing titration protocols in Phase 2 to mimic injectable peptide precedents (dosing up drug while down-titrating calcium/Vitamin D supplements).
    • Pipeline Expansion: Moving from single-indication focus to broader signal-finding for mast cell targets (migraine, asthma, interstitial cystitis).
  • Risks and Headwinds to Outlook:

    • Mechanism Specificity: Encalerate's potential success in post-surgical patients remains uncertain pending Phase 3 data; SCP-479 relies on full PTH replacement which may be viewed differently by payers vs. calcium-balancing agents.
    • Safety Signals: SCP-204 preclinical GLP toxicology showed signs of exaggerated on-target pharmacology (hypothyroidism), which must be managed in clinical dosing.
    • Development Timelines: Delays in chronic toxicology studies or unexpected Phase 1 readouts could impact the 2026/2027 Phase 2 start targets.
    • Competitive Uncertainty: Unknown efficacy of Encalerate in the specific post-surgical population; potential for other oral competitors to emerge.
  • Management Tone on the Future:

    • Confidence: High confidence in the platform's ability to solve historical difficulties in creating oral small molecules for GPCRs (PTH1R, TSHR).
    • Optimism: Describing SCP-479 and SCP-204 as having "great activity" and "best-in-class profile" potential; expressing excitement about the Novartis collaboration progress.
    • Strategic Shift: Willingness to pivot from large CSU studies for SCP-631 to smaller, faster signal-finding studies for migraine and other indications.
  • Miscellaneous:

    • Trial Locations: SCP-479 Phase 1 conducted in Australia.
    • Biomarkers: Expectation of endocrine feedback loops to drive biomarker changes (PTH down/Calcium up for SCP-479; TSH up/Thyroid hormones down for SCP-204).
Company
SEPTERNA INC
Keywords
SEPTERNA INC